(Q43946746)

28 November 2017

The safety of azithromycin in the treatment of adults with community-acquired respiratory tract infections (English)

1 reference

28 November 2017

0 references

Glenda Treadway

1

1 reference

PubMed ID

11932140

28 November 2017

Dennis Pontani

series ordinal

2

1 reference

PubMed ID

11932140

28 November 2017

Arlene Reisman

series ordinal

3

1 reference

28 November 2017

1 March 2002

1 reference

International Journal of Antimicrobial Agents

28 November 2017

1 reference

28 November 2017

19

1 reference

28 November 2017

3

1 reference

28 November 2017

189-194

1 reference

Adverse effects of macrolide antibacterials

28 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900490-3

7 January 2021

Erythromycin and the gut.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900490-3

7 January 2021

Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900490-3

7 January 2021

In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR).

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900490-3

7 January 2021

In vitro activity of azithromycin against clinical isolates of Legionella species

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900490-3

7 January 2021

In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900490-3

7 January 2021

Efficacy and safety of azithromycin versus phenoxymethylpenicillin in the treatment of acute maxillary sinusitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900490-3

7 January 2021

An open comparative study of azithromycin and roxithromycin in the treatment of acute upper respiratory tract infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900490-3

7 January 2021

An open comparative study of azithromycin versus cefaclor in the treatment of patients with upper respiratory tract infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900490-3

7 January 2021

Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900490-3

7 January 2021

Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900490-3

7 January 2021

Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900490-3

7 January 2021

A randomized, comparative study to evaluate the efficacy and tolerability of a 3-day course of azithromycin versus a 10-day course of co-amoxiclav as treatment of adult patients with lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900490-3

7 January 2021

Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900490-3

7 January 2021

10.1016/S0924-8579(01)00490-3

Identifiers

DOI

1 reference

28 November 2017

1 reference

PubMed ID

11932140